FDA's food labeling rules require a Nutrition Facts panel and other label elements and restrict nutrient and 'healthy' claims to foods meeting FDA criteria; the amended 'healthy' definition is effective April 28, 2025 with compliance required by Feb. 25, 2028.
21 CFR Part 201 requires OTC drug labels to carry a standardized Drug Facts panel and prescription labels to carry 'Rx only', with label claims consistent with approved labeling.
Limits dandruff, seborrheic dermatitis and psoriasis claims to those the OTC monograph permits for the product's active ingredient, and bars cure or permanence claims.
Limits antiperspirant claims to monograph-permitted wetness claims, bars sweat claims for deodorants without an active, and requires the kidney-disease warning on labels.
Requires beverage names to match juice content and bottled-water identity standards, a percent-juice statement on juice beverage labels, and 'healthy' only where FDA criteria are met.
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed.
Sunscreen, acne and dandruff products must use FDA-permitted claim terms and stay within monograph uses; full Drug Facts statements apply to labels, not to every ad.
Cosmetic labels must show identity, net quantity, an ingredient declaration in descending order, the responsible business's name and place, a MoCRA adverse-event contact, and required warnings.
Bars cosmetic marketing claims that assert disease treatment or a change in body structure or function, which would make the product an unapproved drug.
Cosmetics may not contain prohibited or restricted ingredients or unlisted colors, must carry 21 CFR 740 warnings where required, and may not make drug claims.
Requires company-owned digital promotion of Rx drugs and restricted devices to give the most serious risks alongside benefits, the established name, and access to full prescribing information.
Requires consumer TV, radio and video prescription drug ads to present the major statement of risks clearly, conspicuously and neutrally and to provide a brief summary or adequate provision.
Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Device promotion must not make false, absolute or unsubstantiated performance, safety or superiority claims; quantified and comparative claims need a cited basis.
FDA food additive rules require additives to be approved or GRAS, and labeling rules require certified colors and preservatives to be declared properly; 'no artificial' or 'no preservative' claims must match the ingredient list.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Under FDA's longstanding informal policy, 'natural' on food means nothing artificial or synthetic, including any added color, has been added that would not normally be expected; misleading 'natural' claims misbrand food.
Nutrient content claims such as 'low fat', 'sugar free', 'light' and 'healthy' may be used only when the food meets FDA's defined per-serving criteria, with reference statements on comparative claims and a disclosure statement when disqualifying nutrient levels are exceeded.
Packaged food labels must carry identity, net contents, ingredients, a major-allergen declaration (nine allergens including sesame), the responsible firm's name and address, and Nutrition Facts unless exempt.
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation.
A food sold under a name defined by an FDA standard of identity must meet that standard; non-conforming products must use a different or qualified name, or 'imitation' when nutritionally inferior.
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
Homeopathic products are drugs; marketing must not imply FDA approval, must not promote them for serious diseases, and efficacy claims must be scientifically supported or clearly qualified as based only on homeopathic theory.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Device promotion must describe FDA status accurately (cleared, approved or De Novo authorized), must not imply approval from registration, must not promote investigational devices, and restricted-device ads need a brief risk statement.
Cosmetic marketing must stay within cosmetic (appearance) claims, must not imply FDA approval, and cosmetic labels must include MoCRA adverse-event contact information.
Under MoCRA, cosmetic labels must give a US address, US phone number or electronic contact for adverse-event reports, and professional-use products must say they are for licensed professionals only.
Health software marketing must not claim FDA status it lacks, make diagnostic or disease claims for wellness or excluded software, or claim to replace clinicians.
Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.
Food labels must use the current Nutrition Facts format with RACC-based servings, and nutrient content and 'healthy' claims must meet FDA definitions and be consistent with the label.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
GLP-1 ads must not promote diabetes-only brands for weight loss, imply compounded products are FDA-approved or equivalent to brands, guarantee results, or omit risk information for branded drugs.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
OTC drug labels must carry a Drug Facts panel in the 21 CFR 201.66 format with the ingredient-specific warnings, such as the acetaminophen liver warning and aspirin Reye's syndrome warning.
Limits OTC monograph drug claims (sunscreens, acne, antiperspirants) to permitted indications and terms, bans terms such as 'sunblock' and 'waterproof', and requires Drug Facts on labeling.
Requires prescription drug advertising in all channels to present risks with fair balance, include a brief summary or equivalent, and avoid overstated, off-label or unsupported claims.
SaMD marketing must use the correct FDA status term (approved only for PMA devices, cleared for 510(k)), must not imply FDA endorsement or treat registration as approval, and must not claim uses beyond the authorized intended use.
Sexual wellness products that make therapeutic, contraceptive or STI-prevention claims are regulated as medical devices and may make those claims only within an FDA clearance or approval.
Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.
Sports supplements may make structure/function claims only with the full FDA disclaimer on labeling and must not make disease or drug-equivalent claims.
US OTC sunscreen labels and promotional copy must use monograph-permitted SPF, broad spectrum and water resistance statements, Drug Facts and required warnings, and avoid prohibited terms like sunblock and waterproof.
Sunscreen marketing must use monograph-consistent claims: no 'sunblock', 'waterproof', 'sweatproof', instant or all-day protection claims, water resistance only as 40 or 80 minutes, and broad-spectrum and skin-cancer claims only for qualifying products.
OTC sunscreens may use only monograph-listed active ingredients within permitted concentrations, and labels must carry a complete Drug Facts panel and, where required, the Skin Cancer/Skin Aging Alert.
Supplement marketing may describe cGMP manufacturing accurately but may not claim FDA approval or certification of the product or facility, which FDA does not give.
Telehealth and online pharmacy ads must not claim or imply that compounded drugs are FDA-approved, generic or equivalent to branded drugs, or proven safe and effective, and ads making drug benefit claims must include risk information.
Tobacco and nicotine ads must carry the required health warnings (20% of ad area for ENDS, cigars and smokeless), may not make light, mild or reduced-risk claims without an FDA modified-risk order, and may not offer free samples or appeal to youth.
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.
Weight-loss product marketing must avoid unrealistic or drug-equivalent claims and banned ingredients, disclose typical results for testimonials, and carry Supplement Facts and the DSHEA disclaimer on labeling.
FDCA Section 403 deems food misbranded if its labeling is false or misleading or lacks required elements such as the statement of identity, net quantity, ingredients, major allergens, manufacturer details and nutrition labeling.
Standardized food names may be used only for products meeting FDA standards of identity; nutritionally inferior substitutes must be labeled 'imitation', while qualified plant-based names are generally allowed.
'Healthy' as an implied nutrient content claim requires a minimum food-group contribution and limits on added sugars, saturated fat and sodium under the updated 21 CFR 101.65(d); old criteria may be used until Feb. 25, 2028.
Plant-based alternatives may use familiar dairy and meat terms when they are clearly qualified as plant-based and do not mislead; several states require such qualifiers, and FDA's plant-based milk nutrient statement guidance is a non-binding recommendation.
Under FALCPA as amended by the FASTER Act, packaged food labels must name the source of each of the nine major food allergens in the ingredient list or a complete 'Contains' statement.
Sunscreen labels and ads in Florida must follow FDA sunscreen rules: no 'sunblock', 'waterproof' or 'sweatproof' claims, stated water-resistance times, and skin cancer claims only for broad spectrum SPF 15+ products.